AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24415445 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 780
Study 22264206 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized oral instruction
Number of subjects: 83
Study 22264206 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized oral instruction
Number of subjects: 83
Study 22264206 — intervention group
Group type: EXPERIMENTAL
Intervention: Written instruction
Number of subjects: 83
Study 22264206 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 83
Study 20440099 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise-detraining group (RDT)
Number of subjects: 22
Study 20440099 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise group (RT)
Number of subjects: 22
Study 20440099 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 22
Study 17524880 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E) 10 mg/d, 15 patients
Number of subjects: 70
Study 17524880 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (L) 50 mg/d, 20 patients
Number of subjects: 70
Study 17524880 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + Losartan (E+L) 10 mg/d + 50 mg/d, 13 patients
Number of subjects: 70
Study 17524880 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication), 22 patients
Number of subjects: 70
Study 16386523 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 26
Study 16386523 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 26
Study 12144582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 0
Study 12144582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 0
Study 12144582 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 10 mg
Number of subjects: 0
Study 12144582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9481855 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-leukocyte-depleted blood products (NLD)
Number of subjects: 129
Study 9481855 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte-depleted blood products (LD)
Number of subjects: 129
Study 9481855 — intervention group
Group type: COMPARATOR
Intervention: Comparison between NLD and LD groups
Number of subjects: 129
Study 9481855 — intervention group
Group type: EXPERIMENTAL
Intervention: NLD patients without a history of previous transfusion
Number of subjects: 129
Study 8535686 — intervention group
Group type: EXPERIMENTAL
Intervention: Prader orchidometer
Number of subjects: 31
Study 8535686 — intervention group
Group type: EXPERIMENTAL
Intervention: Takihara punched‐ring orchidometer
Number of subjects: 31
Study 8535686 — intervention group
Group type: EXPERIMENTAL
Intervention: Seager orchidometer
Number of subjects: 31
Study 8535686 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography (US)
Number of subjects: 31
Study 2796623 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 20 mL of 2% lidocaine + 3 mL normal saline
Number of subjects: 60
Study 2796623 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 20 mL of 2% lidocaine + 1:200000 epinephrine + 5 mL normal saline
Number of subjects: 60
Study 2796623 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 20 mL of 2% lidocaine + 2 mL of fentanyl + 3 mL normal saline
Number of subjects: 60
Study 2796623 — intervention group
Group type: COMPARATOR
Intervention: Group D: 20 mL of 2% lidocaine + 5 mL normal saline
Number of subjects: 60
Study 266502 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly professional mechanical tooth cleaning
Number of subjects: 28
Study 266502 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (no cleaning during the study)
Number of subjects: 28
Study 30817505 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus dexamethasone-soaked nasal packing
Number of subjects: 60
Study 30817505 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 60
Study 29851985 — intervention group
Group type: EXPERIMENTAL
Intervention: RBV (Ribavirin) in combination with ombitasvir/paritaprevir/ritonavir and dasabuvir
Number of subjects: 0
Study 29851985 — intervention group
Group type: EXPERIMENTAL
Intervention: RBV (Ribavirin)
Number of subjects: 0
Study 29851985 — intervention group
Group type: COMPARATOR
Intervention: DAA treatment (ombitasvir/paritaprevir/ritonavir and dasabuvir)
Number of subjects: 0
Study 27029846 — intervention group
Group type: EXPERIMENTAL
Intervention: Elvitegravir (reduced dose of 85 mg) co-administered with cobicistat and atazanavir
Number of subjects: 144
Study 27029846 — intervention group
Group type: COMPARATOR
Intervention: Non-ritonavir-boosted atazanavir
Number of subjects: 144
Study 27029846 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir
Number of subjects: 144
Study 24805892 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight‐supported treadmill plus overground walking practice
Number of subjects: 0
Study 24805892 — intervention group
Group type: COMPARATOR
Intervention: Home‐based exercise
Number of subjects: 0
Study 21665549 — intervention group
Group type: EXPERIMENTAL
Intervention: Declines in lack of knowledge
Number of subjects: 213
Study 21665549 — intervention group
Group type: EXPERIMENTAL
Intervention: Declines in lack of control
Number of subjects: 213
Study 21665549 — intervention group
Group type: EXPERIMENTAL
Intervention: Declines in lack of time
Number of subjects: 213
Study 19209185 — intervention group
Group type: COMPARATOR
Intervention: Paleolithic type diet
Number of subjects: 9
Study 17629069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg) thrice daily for 4 weeks
Number of subjects: 17
Study 17629069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 15059101 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nickel exposure (4 mg)
Number of subjects: 0
Study 15059101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11454246 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mass treatment with single-dose diethylcarbamazine plus ivermectin
Number of subjects: 0
Study 11454246 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mass treatment with single-dose diethylcarbamazine plus ivermectin plus vector control
Number of subjects: 0
Study 11454246 — intervention group
Group type: COMPARATOR
Intervention: Vector control
Number of subjects: 0
Study 9736230 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium polycarbophil (0.62 g/twice daily)
Number of subjects: 28
Study 9736230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7988625 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol (1 mg)
Number of subjects: 48
Study 7988625 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous butorphanol (1 mg)
Number of subjects: 48
Study 7988625 — intervention group
Group type: COMPARATOR
Intervention: Transnasal butorphanol
Number of subjects: 48
Study 7988625 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and transnasal administration
Number of subjects: 48
Study 2919094 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiprostaglandin agents (naproxen)
Number of subjects: 55
Study 2919094 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiprostaglandin agents (pirprofen)
Number of subjects: 55
Study 2919094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 2919094 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiprostaglandin agents (active treatment)
Number of subjects: 55
Study 31227493 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 321
Study 31227493 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic Partial Meniscectomy (APM)
Number of subjects: 321
Study 30976844 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 72
Study 29017595 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally produced enalapril (5-20 mg once daily for 14 days)
Number of subjects: 0
Study 29017595 — intervention group
Group type: COMPARATOR
Intervention: Imported enalapril (5-20 mg once daily for 14 days)
Number of subjects: 0
Study 25136746 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined standard‐dosed Solifenacin and Trospium
Number of subjects: 417
Study 25136746 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 417
Study 24993931 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-operated endovaginal telemonitoring (SOET)
Number of subjects: 121
Study 24993931 — intervention group
Group type: COMPARATOR
Intervention: Traditional monitoring (non-SOET)
Number of subjects: 121
Study 21924576 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based diabetes self-management program
Number of subjects: 463
Study 21924576 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 463
Study 19573247 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized walking programme
Number of subjects: 246
Study 19573247 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised general exercise programme
Number of subjects: 246
Study 19573247 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 246
Study 17468819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antimicrobial prophylaxis alone
Number of subjects: 491
Study 17468819 — intervention group
Group type: COMPARATOR
Intervention: Combined oral and intravenous antimicrobial prophylaxis
Number of subjects: 491
Study 15800157 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant plus olanzapine
Number of subjects: 20
Study 15800157 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant plus placebo
Number of subjects: 20
Study 11804772 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computerized decision aid
Number of subjects: 51
Study 11804772 — intervention group
Group type: COMPARATOR
Intervention: Standard audio‐booklet decision aid
Number of subjects: 51
Study 10690139 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) analgesia
Number of subjects: 1008
Study 10690139 — intervention group
Group type: COMPARATOR
Intervention: Epidural (EPI) analgesia
Number of subjects: 1008
Study 8750244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study 1742537 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MU of interferon three times a week for six months
Number of subjects: 66
Study 1742537 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumption of interferon at the same dosage after relapse
Number of subjects: 66
Study 1742537 — intervention group
Group type: COMPARATOR
Intervention: 3MU of interferon for four months
Number of subjects: 66
Study 7201436 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser treatment for pigment epithelial detachments (6 eyes)
Number of subjects: 26
Study 7201436 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser treatment for subretinal neovascular membranes (7 eyes)
Number of subjects: 26
Study 7201436 — intervention group
Group type: COMPARATOR
Intervention: Control group for pigment epithelial detachments (7 eyes)
Number of subjects: 26
Study 7201436 — intervention group
Group type: COMPARATOR
Intervention: Control group for subretinal neovascular membranes (6 eyes)
Number of subjects: 26
Study 30896417 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group
Number of subjects: 235
Study 28573743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg as one injection every 4 weeks)
Number of subjects: 2570
Study 28573743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg as one injection every 2 weeks)
Number of subjects: 2570
Study 28573743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2570
Study 28573743 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (50 mg twice weekly)
Number of subjects: 2570
Study 28573743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (both dosing regimens)
Number of subjects: 2570
Study 25080876 — intervention group
Group type: EXPERIMENTAL
Intervention: IA clodronate 2 mg
Number of subjects: 80
Study 25080876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 80
Study 23293924 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) imaging
Number of subjects: 50
Study 23293924 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D fusion imaging
Number of subjects: 50
Study 23293924 — intervention group
Group type: COMPARATOR
Intervention: LGE imaging
Number of subjects: 50
Study 23293924 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 50
Study 23293924 — intervention group
Group type: COMPARATOR
Intervention: Cryoablation
Number of subjects: 50
Study 21070569 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin
Number of subjects: 96
Study 19459829 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg metoclopramide ODT
Number of subjects: 41
Study 19459829 — intervention group
Group type: COMPARATOR
Intervention: Conventional 10-mg metoclopramide tablet
Number of subjects: 41
Study 17470680 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine in combination with lapatinib
Number of subjects: 0
Study 17470680 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine in combination with trastuzumab
Number of subjects: 0
Study 17470680 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine in combination with bevacizumab
Number of subjects: 0
Study 17470680 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine monotherapy
Number of subjects: 0
Study 15522362 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 454
Study 15522362 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 454
Study 11441770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 11441770 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 0
Study 11441770 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 0
Study 11441770 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital/couples psychotherapy
Number of subjects: 0
Study 11441770 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0
Study 9693891 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal gastroscopy
Number of subjects: 181
Study 9693891 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral gastroscopy
Number of subjects: 181
Study 7943066 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion (800 ml bolus of normal saline followed by continuous infusion at 180 ml/hr)
Number of subjects: 124
Study 7943066 — intervention group
Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 124
Study 3211167 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophyllin treatment administered orally for one week
Number of subjects: 33
Study 3211167 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aminophyllin treatment)
Number of subjects: 33
Study 3211167 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophyllin treatment continued for at least 6 weeks, followed by monitoring one week after discontinuation
Number of subjects: 33
Study 30422942 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-directed tablet computer distraction
Number of subjects: 77
Study 30422942 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive care
Number of subjects: 77
Study 30422942 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-directed tablet computer distraction (unrestrained)
Number of subjects: 77
Study 30422942 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive care (unrestrained)
Number of subjects: 77
Study 31677213 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-term pre-schoolers
Number of subjects: 811
Study 31677213 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-schoolers who reported asthma in the first year of life
Number of subjects: 811
Study 29637918 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 2000IU/day for 6 months
Number of subjects: 112
Study 29637918 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 112
Study 28877949 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneous for 5 days
Number of subjects: 32
Study 28877949 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular methylprednisolone 120 mg
Number of subjects: 32
Study 26591677 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng capsule (XFC)
Number of subjects: 304
Study 26591677 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide (LEF)
Number of subjects: 304
Study 23645012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic sealant (n=10)
Number of subjects: 20
Study 23645012 — intervention group
Group type: COMPARATOR
Intervention: Thrombin solution (n=10)
Number of subjects: 20
Study 21311513 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry flavoured acidic gum
Number of subjects: 8
Study 21311513 — intervention group
Group type: COMPARATOR
Intervention: Peppermint flavoured non-acidic gum
Number of subjects: 8
Study 19398604 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg on the first day and then 75 mg once daily for 3 consecutive days)
Number of subjects: 12
Study 19398604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16188496 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk test (6-MWT)
Number of subjects: 120
Study 16188496 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal incremental treadmill exercise test with metabolic gas exchange measurements
Number of subjects: 120
Study 15232812 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous intercostal nerve block using plain bupivacaine 0.375%
Number of subjects: 52
Study 15232812 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous intercostal nerve block using bupivacaine 0.375% in dextran 40
Number of subjects: 52
Study 15232812 — intervention group
Group type: COMPARATOR
Intervention: No intercostal blockade (retrospective group)
Number of subjects: 52
Study 11506755 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine visits
Number of subjects: 107
Study 11506755 — intervention group
Group type: COMPARATOR
Intervention: In-person visits
Number of subjects: 107
Study 9229884 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal invitations with user fee ($40-$60 US)
Number of subjects: 585
Study 9229884 — intervention group
Group type: EXPERIMENTAL
Intervention: Free influenza vaccination invitation
Number of subjects: 585
Study 9229884 — intervention group
Group type: COMPARATOR
Intervention: Control group (vaccinated on their own request, paying usual fee)
Number of subjects: 585
Study 7955806 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (0.25 to 1.0 mg)
Number of subjects: 5
Study 7955806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 7955806 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 5
Study 2701751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried thyroid gland (Thyroideum‐Polfa)
Number of subjects: 20
Study 2701751 — intervention group
Group type: COMPARATOR
Intervention: Sodium salt of L‐thyroxine (L‐T4)
Number of subjects: 20
Study 30295870 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife Surgery (GKS)
Number of subjects: 1351
Study 30295870 — intervention group
Group type: COMPARATOR
Intervention: Medical management only (as per ARUBA trial)
Number of subjects: 1351
Study 29147070 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychobiotics oral suspension group (POSG)
Number of subjects: 0
Study 29147070 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (CTG)
Number of subjects: 0
Study 29147070 — intervention group
Group type: COMPARATOR
Intervention: Dietary treatment group (DTG)
Number of subjects: 0
Study 26305617 — intervention group
Group type: EXPERIMENTAL
Intervention: TZD use (Rosiglitazone or Pioglitazone) for 1-2 years
Number of subjects: 6865
Study 26305617 — intervention group
Group type: EXPERIMENTAL
Intervention: TZD use (Rosiglitazone or Pioglitazone) for >2 years
Number of subjects: 6865
Study 26305617 — intervention group
Group type: EXPERIMENTAL
Intervention: TZD discontinuation for 1-2 years
Number of subjects: 6865
Study 26305617 — intervention group
Group type: EXPERIMENTAL
Intervention: TZD discontinuation for >2 years
Number of subjects: 6865
Study 26305617 — intervention group
Group type: COMPARATOR
Intervention: TZD use and discontinuation
Number of subjects: 6865
Study 24289513 — intervention group
Group type: EXPERIMENTAL
Intervention: Early, goal directed, protocolised resuscitation
Number of subjects: 0
Study 24289513 — intervention group
Group type: COMPARATOR
Intervention: Usual resuscitation
Number of subjects: 0
Study 21699951 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 μg HA/strain TIV ID
Number of subjects: 1592
Study 21699951 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 μg HA/strain TIV ID
Number of subjects: 1592
Study 21699951 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 μg HA/strain TIV ID
Number of subjects: 1592
Study 21699951 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 μg HA/strain TIV ID (50-64 years subgroup)
Number of subjects: 1592
Study 21699951 — intervention group
Group type: COMPARATOR
Intervention: Standard 15 μg HA/strain TIV IM
Number of subjects: 1592
Study 21699951 — intervention group
Group type: EXPERIMENTAL
Intervention: ID administration
Number of subjects: 1592
Study 21699951 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV ID administration experience
Number of subjects: 1592
Study 18298480 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 302
Study 18298480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BNP and pneumonia severity index (PSI)
Number of subjects: 302
Study 18298480 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 302
Study 17176529 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 0